Glaukos Q4 record sales $143.1M (+36% YoY); reaffirms FY2026 guidance $600-620M

GLAUKOS Corp

2025-FY EPS reported -$3.28 revenue$507,442,000

Q4 net sales $143.1M (record), +36% YoY; full year $507.4M, +32% YoY.
GAAP net loss $133.7M ($2.32/sh) includes $112.9M non-cash impairment on Avedro intangible.
Non-GAAP net loss improved to $16.4M ($0.28/sh) from $22.2M ($0.40) in Q4 2024.
U.S. Glaucoma sales record $86.4M, +53% YoY; strong growth from iDose TR.
Ended Q4 with $282.6M cash, no debt; 2026 revenue guidance reaffirmed at $600-620M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.